Osang Healthcare (036220) Fundamentals 2026 — Revenue Analysis | SniperIQ
Osang Healthcare (036220) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩80.6B, trading at ₩5860.00 on the KOE. This SniperIQ fundamentals page covers Osang Healthcare's valuation, profitability (net margin -3.7%), revenue (₩128.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Osang Healthcare's market cap?
Osang Healthcare (036220) has a market capitalization of approximately ₩80.6B, trading at ₩5860.00 on the KOE. Market cap moves with the live share price.
What is Osang Healthcare's P/E ratio?
Osang Healthcare's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Osang Healthcare?
Osang Healthcare runs a net profit margin of -3.7%, a gross margin of 37.8%, and an operating margin of -5.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Osang Healthcare generate?
Osang Healthcare reported revenue of ₩128.6B for fiscal year 2025, with net income of ₩3.1B and earnings per share (EPS) of 226. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Osang Healthcare pay a dividend?
Osang Healthcare offers a trailing dividend yield of about 3.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Osang Healthcare financially healthy?
Osang Healthcare carries a debt-to-equity ratio of 0.17x and a current ratio of 2.59x, with a market beta of 0.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Osang Healthcare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Osang Healthcare (036220) the key facts are: market cap ₩80.6B, revenue ₩128.6B, 52-week range 5200-19490. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Osang Healthcare's full fundamentals live
Get Osang Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.